小剂量氢氯噻嗪联合厄贝沙坦治疗原发性高血压的临床观察

doi:10.3969/j.issn.1006-7795.2018.01.026

摘要/Abstract

摘要： 目的观察小剂量氢氯噻嗪联合厄贝沙坦治疗原发性高血压（essential hypertension，EH）的临床效果，研究其对空腹血糖（fasting plasma glucose，FPG）、血脂、电解质和尿酸（uric acid，UA）的影响。方法采用数字表法将94例EH患者随机分为对照组（47例）和试验组（47例）。对照组采用厄贝沙坦治疗，试验组采用厄贝沙坦联合小剂量氢氯噻嗪治疗。观察并比较治疗2个月前后2组患者血压变化和FPG、总胆固醇（total cholesterol，TC）、三酰甘油（triglyceride，TG）、高密度脂蛋白胆固醇（high density lipoprotein-cholesterol，HDL-C）、低密度脂蛋白胆固醇（low density lipoprotein-cholesterol，LDL-C）、血钠（Na⁺）、血氯（Cl^-）、血钾（K⁺）和血UA等生物化学指标的变化。结果治疗后2组患者血压均较治疗前明显下降（P<0.05），试验组治疗后收缩压（systolic blood pressure，SBP）和舒张压（diastolic blood pressure，DBP）分别为（132.15±12.30）mmHg（1 mmHg=0.133 kPa）和（82.89±7.26）mmHg，对照组治疗后SBP和DBP分别为（139.85±13.89）mmHg和（88.02±8.77）mmHg，但试验组的降压效果更显著（P<0.05）。试验组治疗总有效率95.74%，明显高于对照组78.72%，组间差异有统计学意义（P<0.05）。2组患者治疗后血清FPG、血脂、电解质及UA相比差异均无统计学意义（P>0.05），试验组患者治疗前后上述生物化学指标差异无统计学意义（P>0.05）。结论小剂量氢氯噻嗪联合厄贝沙坦治疗原发性高血压，能显著提高治疗效果，且未发现对空腹血糖、血脂、电解质或尿酸有明显影响。

关键词: 氢氯噻嗪, 厄贝沙坦, 原发性高血压

Abstract: Objective To observe the efficacy of low-dose hydrochlorothiazide combining with irbesartan on essential hypertension(EH), and to investigate its effects on fasting plasma glucose(FPG), blood liquid, electrolyte and uric acid(UA).Methods A total of 94 EH patients were randomly divided into control group (n=47) and study group (n=47). Control group was treated with irbesartan, while study group was treated with low-dose hydrochlorothiazide combining irbesartan. Curative effects of blood pressure and parameters of FPG, total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), Na⁺, Cl^-, K⁺ and UA were analyzed and compared between the two groups before and after 2 months of treatment.Results Compared with before treatment, blood pressure of two group were significantly decreased after treatment (P<0.05), and after treatment the systolic blood pressure and diastolic blood pressure of study group were (132.15±12.30)mmHg (1 mmHg=0.133 kPa) and (82.89±7.26)mmHg, and the systolic and diastolic blood pressure of control group were (139.85±13.89)mmHg and (88.02±8.77)mmHg, but the decrease of blood pressure of study group was more significant (P<0.05). The total effective rate of study group was 95.74%, significantly higher than that of control group (78.72%), there was statistical significance (P<0.05). Before and after treatment, the levels of FPG, blood liquid, electrolyte and UA in two groups had no significant difference (P>0.05), and those in study group also had no significant difference before and after treatment (P>0.05).Conclusion Low-dose hydrochlorothiazide combining with irbesartan in the treatment of EH, can significantly improve the crutive effect, and has no significant influence on FPG, blood liquid, electrolyte and UA.

Key words: hydrochlorothiazide, irbesartan, essential hypertension

中图分类号:

R544.1

吕曼. 小剂量氢氯噻嗪联合厄贝沙坦治疗原发性高血压的临床观察[J]. 首都医科大学学报, 2018, 39(1): 148-152.

Lyu Man. Clinical observation on the effects of the treatment of low-dose hydrochlorothiazide combining with irbesartan on essential hypertension[J]. Journal of Capital Medical University, 2018, 39(1): 148-152.

参考文献

[1] 中国高血压防治指南修订委员会. 中国高血压防治指南2010年[J].中华心血管病杂志,2011,39(7):579-616.
[2] 中华心血管病杂志编委会心血管药物对策专题组.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11.
[3] 吴江.抗高血压药物联合用药研究进展[J].中国药事,2012,26(1):80-83.
[4] 杨华.高血压患者联合用药的禁忌[J].中西医结合心血管病杂志,2017,5(12):23-26.
[5] 张万义,宋安洋,周明龙.不同联合用药对老年单纯收缩期高血压患者大动脉僵硬度的疗效比较[J].中华老年心脑血管病杂志,2016,18(8):829-832.
[6] 王磊,魏新伟,于芳.不同降压药物联合治疗对老年高血压患者血压变异性的影响[J].天津医药,2016,44(1):105-109.
[7] 张妮,刘蔚.门诊高血压患者联合用药的调查分析[J].中国临床医生杂志,2015,43(6):48-50.
[8] 黄小华.厄贝沙坦氢氯噻嗪复方片剂治疗原发性高血压的临床效果观察[J].当代医学,2015,21(16):122-123.
[9] 李伯庆.厄贝沙坦氢氯噻嗪和福辛普利治疗原发性高血压的疗效比较[J].成都医学院学报,2015,10(3):346-349.
[10] 宋海宁,赖海燕,李茜.依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(16):1563-1565.
[11] 杨政杰,秦娴,全文超,等.奥美沙坦联合氢氯噻嗪对原发性高血压患者及左心室肥厚的影响[J].中国基层医药,2011,18(22):3033-3034.
[12] 张陶丽,张春晓.厄贝沙坦联合苯磺酸氨氯地平治疗老年糖尿病合并高血压伴高尿酸血症[J].中国临床医生,2011,39(12):25-27.
[13] 郭爱玲.氢氯噻嗪及氢氯噻嗪与依那普利合用对轻中度高血压病患者血脂及电解质的影响[J].中西医结合心脑血管病杂志,2010,8(7):860-861.
[14] Huang Q F, Sheng C S, Li Y, et al.Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension[J].Drugs R D, 2013,13(2):109-107.
[15] Malacco E, Omboni S, Parati G. Blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy:a randomized, double-blind, controlled, parallel group, noninferiority trial[J]. Int J Hypertens, 2015, 2015:139456.
[16] Agabiti-Rosei E, Manolis A, Zava D, et al. Zofenopril plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients[J]. Adv Ther, 2014,31(2):217-233.
[17] Al Balushi K A, Habib J Q, Al-Zakwani I. Comparative efficacy of irbesartan/hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure:a retrospective observational study in oman[J]. Med Princ Pract, 2013,22(3):265-269.